Saturday 17 October 2026 Export BOLT’s income statement to Excel — free account

Bolt Biotherapeutics, Inc.

In the quarter to June 2026, revenue fell 99.7%, EPS fell 2.47%, free cash flow grew 38.9% and total debt fell 14.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

4.06 0.18 −4.25%

Follow BOLT

Alert me

Market cap: $8.2M
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 4/9
Altman Z: −12.67
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01

Total sells 0.13

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	2	—	—	—	—	—	2	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	3	—

Insider Ownership 3.02%

Capital & Financial Ratios $m

Market Cap 8.17

Revenue 4.70

Net Income (28.74)

Free Cash Flow (30.82)

Net Debt 0.74

Current Ratio 2.61

Debt/Equity 1.47

P/E ratio 0.00

Fwd P/E (0.02)

P/S ratio 1.46

P/B ratio 0.54

Past 5Y EPS Growth —

This Y EPS Growth (0.20%)

Next Y EPS Growth (12.89%)

Next Y revenue growth (100.00%)

Next 5Y EPS Growth (19.99%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 14.13%

10-year low 10-year high

P/B against its own 10 years 85.22%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	102	48	28	18
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	106	51	30	21

	2023	2024	2025	Q'26
Payables	3	2	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	20	16	8	8

Compound Annual Growth %

	10y	5y	3y
Sales	—	101.61%	10.33%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	137.74%	(46.34%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	2	2	3	8
’24	5	1	1	0	8
’23	2	1	3	2	8
’22	1	1	2	1	6
’21	—	—	1	1	1
’20	0	0	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(7)	—	—	—
’25	(13)	(10)	(10)	(7)	(40)
’24	(17)	(16)	(14)	(14)	(61)
’23	(23)	(15)	(17)	(14)	(70)
’22	(24)	(21)	(13)	(18)	(77)
’21	(17)	(4)	(19)	(18)	(57)
’20	(10)	(12)	(13)	(13)	(47)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(6)	—	—	—
’25	(12)	(10)	(10)	(7)	(39)
’24	(17)	(16)	(14)	(14)	(61)
’23	(23)	(15)	(17)	(14)	(70)
’22	(25)	(21)	(14)	(18)	(78)
’21	(17)	(5)	(20)	(18)	(59)
’20	(10)	(13)	(14)	(14)	(51)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(4.31)	(4.57)	—	—	—
’25	(5.80)	(4.46)	(3.72)	(3.84)	(17.85)
’24	(5.60)	(11.20)	(8.00)	(8.40)	(33.00)
’23	(9.00)	(9.60)	(8.60)	(9.40)	(36.60)
’22	(12.80)	(12.20)	(11.60)	(10.60)	(47.20)
’21	(22.80)	(12.80)	(12.60)	(14.60)	(59.40)
’20	(83.13)	(105.88)	(94.71)	(291.60)	(577.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	79.20	23.60	16.80	9.50	4.41	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	861.40	99.80	40.60	31.20	12.60
People
People	Employees	—	—	—	—	65	91	94	100	52	23
	Revenue/emp, $m	—	—	—	0.00	0.00	0.01	0.06	0.08	0.15	0.33
Income, $m
Income, $m	Revenue	—	—	—	0	0	1	6	8	8	8
	Gross margin, %	—	—	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(12)	(30)	(61)	(99)	(88)	(69)	(63)	(33)
	EBT margin, %	—	—	0.00	(14,180.00)	(26,289.18)	(7,824.68)	(1,537.76)	(878.58)	(820.78)	(433.74)
	Net income	—	0	(12)	(30)	(61)	(99)	(88)	(69)	(63)	(33)
	Depreciation	—	—	0	0	1	4	2	(3)	(1)	1
Per share, $
Per share, $	Revenue	—	—	0.00	2.16	2.20	0.76	3.07	4.17	4.03	4.12
	Earnings	—	—	(0.33)	(305.94)	(577.80)	(59.40)	(47.20)	(36.60)	(33.00)	(17.85)
	Cash flow	—	—	(0.28)	(264.22)	(450.12)	(34.38)	(40.96)	(36.77)	(32.11)	(21.31)
	Capex	—	—	0.00	(5.10)	(31.04)	(1.41)	(1.05)	(0.11)	0.06	0.48
	Free cash flow	—	—	(0.28)	(269.32)	(481.16)	(35.79)	(42.00)	(36.88)	(32.05)	(20.83)
	Book value	—	—	0.35	317.54	3.32	150.68	91.82	59.63	29.96	14.17
	Shares, m	—	—	35	0	0	2	2	2	2	2
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	0.00	109.10	8.93	5.57	2.66	1.33
	P/B	—	—	—	0.00	0.00	0.65	0.30	0.39	0.36	0.39
	EV/Sales	—	—	—	0.00	0.00	(1.14)	(17.02)	(5.19)	(0.61)	0.35
	EV/FCF	—	—	—	(1.09)	(1.09)	0.03	1.24	0.59	0.08	(0.07)
Cash, $m
Cash, $m	Operating cash flow	—	—	(10)	(26)	(47)	(57)	(77)	(70)	(61)	(40)
	Capex	—	—	0	(1)	(3)	(2)	(2)	0	0	1
	Free cash flow	—	—	(10)	(27)	(51)	(59)	(78)	(70)	(61)	(39)
Balance, $m
Balance, $m	Working capital	—	—	11	27	14	168	150	85	35	22
	Total debt	—	—	0	7	9	22	20	17	23	20
	Net debt	—	—	(14)	(28)	(13)	(164)	(149)	(85)	(25)	(8)
	Shareholders’ equity	—	—	12	32	0	250	172	113	57	27
Returns, %
Returns, %	ROA	—	—	(145.09)	(94.65)	(127.86)	(55.66)	(32.90)	(35.71)	(48.66)	(42.69)
	ROIC	—	—	0.00	(493.51)	0.00	(67.63)	(247.18)	(170.15)	(142.45)	(119.22)
	ROE	—	—	37.51	98.68	80.54	(135.83)	(41.79)	(48.69)	(74.28)	(79.75)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CSCIF COSCIENS Biopharma Inc.	$8.6M	1.0×	—	+30.04% (above 0%: growing)	n/m	+113.30% (above 0%: growing)	55.27%	13.43%	Compare
IMRN IMMURON	$8.3M	— (loss-making)	—	+757.00% (above 0%: growing)	+12.00% (above 0%: growing)	+42.55% (above 0%: growing)	72.16%	0.00%	Compare
ADIL Adial Pharmaceuticals, Inc.	$8.3M	— (loss-making)	—	—	n/m	−263.66% (below 0%: shrinking)	0.00%	0.00%	Compare
BOLT Bolt Biotherapeutics, Inc.	$8.2M	— (loss-making)	— (loss-making)	−99.72% (below 0%: shrinking)	n/m	+38.87% (above 0%: growing)	100.00%	(167,480.00%)
SNTI Senti Biosciences, Inc.	$8.1M	— (loss-making)	— (loss-making)	−98.68% (below 0%: shrinking)	n/m	−7.48% (below 0%: shrinking)	100.00%	(85,229.41%)	Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR	$8.1M	— (loss-making)	—	—	n/m	−510.28% (below 0%: shrinking)	0.00%	0.00%	Compare
XTLB XTL Biopharmaceuticals Ltd.	$8.1M	— (loss-making)	—	−39.32% (below 0%: shrinking)	n/m	+46.78% (above 0%: growing)	0.00%	0.00%	Compare
KPTI Karyopharm Therapeutics Inc.	$8.0M	— (loss-making)	— (loss-making)	−11.86% (below 0%: shrinking)	n/m	−33.34% (below 0%: shrinking)	96.75%	(67.38%)	Compare
CNSP CNS Pharmaceuticals, Inc.	$7.9M	— (loss-making)	—	—	n/m	+33.70% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$8.1M	—	—	−11.86%	—	+13.11%	27.64%	0.00%

All 614 Biotechnology stocks →

Bolt Biotherapeutics, Inc. (BOLT) key facts

Concern: Bolt Biotherapeutics, Inc. reported a net loss of $33.4 million, or a loss of $17.85 per share, for fiscal 2025.
Bolt Biotherapeutics, Inc. (BOLT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BOLT traded at $4.06, a market capitalization of $8.2 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.5× sales.
Return on equity was −79.8% and debt-to-equity 1.47.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −12.67 (distress zone) for fiscal 2025.